← All organizations
Highest phase reached
Phase 2
First clinical trial
Mar 1, 2016Last known activity
Dec 1, 2016
Timeline
2010s
- Jul 1, 2013
Shenzhen Hank Bioengineering Institute— Founded
Drugs by trial phase (7 distinct, 26 trials)
Phase 2 (7 own, 0 via acquisition)
Indications
Studied for
- Breast Neoplasms
- Carcinoma, Hepatocellular
- Carcinoma, Non-Small-Cell Lung
- Carcinoma, Ovarian Epithelial
- Carcinoma, Renal Cell
- Colorectal Neoplasms
- Esophageal Neoplasms
- Laryngeal Neoplasms
- Liver Neoplasms
- Lung Neoplasms
- Lymphoma
- Melanoma
- Nasopharyngeal Carcinoma
- Nasopharyngeal Neoplasms
- Neoplasms
- Ovarian Neoplasms
- Pancreatic Neoplasms
- Pharyngeal Neoplasms
- Sarcoma
- Tongue Neoplasms
- Uterine Cervical Neoplasms
Recent trials (26)
- NCT03008343CollaboratorPhase 1/Phase 2Dec 1, 2016
- NCT03007836CollaboratorPhase 1/Phase 2Dec 1, 2016
- NCT03007823CollaboratorPhase 1/Phase 2Dec 1, 2016
- NCT03007875CollaboratorPhase 1/Phase 2Dec 1, 2016
- NCT03008499CollaboratorPhase 1/Phase 2Dec 1, 2016
- NCT03008330CollaboratorPhase 1/Phase 2Dec 1, 2016
- NCT03008304CollaboratorPhase 1/Phase 2Dec 1, 2016
- NCT02857920CollaboratorPhase 1/Phase 2Aug 1, 2016
- NCT02844335CollaboratorPhase 1/Phase 2Jul 1, 2016
- NCT02843204CollaboratorPhase 1/Phase 2Jul 1, 2016
- NCT02843126CollaboratorPhase 1/Phase 2Jul 1, 2016
- NCT02849340CollaboratorPhase 1/Phase 2Jul 1, 2016
- NCT02845856CollaboratorPhase 1/Phase 2Jul 1, 2016
- NCT02853903CollaboratorPhase 2Jul 1, 2016
- NCT02849379CollaboratorPhase 1/Phase 2Jul 1, 2016
Details
- Founded
- Shenzhen, CN Jul 1, 2013
- Last known activity
- Dec 1, 2016